Developing breakthrough treatments for fibrotic diseases


Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. By leveraging its powerful product engine, Pliant’s mission is to prevent or even reverse fibrosis, restoring organ function. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression and fuel biomarker discovery for efficient clinical trial design.


Year Invested: 2016
Location: Redwood, Calif.
Visit: www.pliantrx.com

Recent News

May 22, 2018
Pliant Therapeutics Presents Idiopathic Pulmonary Fibrosis Biomarker Discovery Research at American Thoracic Society 2018 International Conference

May 8, 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and √Čric Lefebvre as Chief Medical Officer

September 26, 2017
Pliant Appoints Katerina Leftheris, Ph.D., as Vice President of Chemistry and John Curnutte, M.D., Ph.D. to the Board of Directors

Read More News

Associated Team Members

Neil Exter
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner